Chorea Market Research Report - Global Forecast till 2027

Chorea Market Research Information: by Type (Huntington’s disease, Sydenham’s chorea, Drug-induced chorea), Treatment (Medical Care, Surgical Care), Distribution Channel (Hospitals, Diagnostic Centers, Drug Stores, Pharmacies) – Global forecast till 2027

ID: MRFR/HC/3782-HCR | | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Chorea is an abnormal involuntary movement characterized by brief, abrupt, unpredictable, irregular, non-stereotyped movements. Chorea may worsen with anxiety and voluntary movements, and subsides during sleep The major causes of chorea include use of oral contraceptives, pregnancy, autoimmune disorders, paraneoplastic syndromes, hyperthyroidism, hypoparathyroidism, and hyperglycemia.


According to a study published in Neurodegenerative Disease Management journal in 2016, prevalence of Huntington's disease (HD) is lower in Asian populations as compared to Western Europe, North America, and Australia.


Due to the rising burden of chorea, and related diseases, various pharmaceutical companies, and devices manufacturers have come up with novel technological advancements. For instance, on April 3, 2017, Teva Pharmaceutical Industries Ltd. received FDA approval for AUSTEDO™ (deutetrabenazine) for the treatment of chorea associated with Huntington’s disease (HD). Huntington’s disease (HD) affects more than 35,000 people in the United States. Various other companies such as Pfizer is also targeting this condition by developing novel drugs.


Notably, growing public awareness, and technological advancements are the key factors driving the chorea market. Nowadays, people are becoming more aware of different types of neurological disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and health concious. Thus, increasing awareness has provided a push to the growth of the market. In September, 2017, Medtronic received FDA approval for Intellis platform. Medtronic offers a broad range of product portfolio such as RestoreSensor SureScan MRI* neurostimulator, RESTOREULTRA SURESCAN MRI NEUROSTIMULATOR, RESTOREADVANCED SURESCAN MRI NEUROSTIMULATOR, and Intellis Platform.


Various other factors such as increasing incidence of neurological disorders, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement are continuously contributing to the growth of the global chorea market.


Despite these drivers, there are some issues associated with chorea market. Some of the challenges in research and development, cost of treatment, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.


It is estimated that the chorea market is expected to grow at a CAGR 11.4% during the forecast period of 2017-2023.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation


The global chorea market is segmented on the basis of type, treatment, and distribution channels.


On the basis of the type, the market is classified as Huntington’s disease, Rheumatic (Sydenham’s chorea), and Drug-induced chorea.


On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into neuroleptics, dopamine-depleting agents, GABAergic drugs, coenzyme Q10, intravenous immunoglobulin, and plasmapheresis. The sub segments neuroleptic includes, typical neuroleptics, and atypical neuroleptics. The surgical care is further segmented into deep brain stimulation, and cell transplantation.


On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.


Key Players


Some of key the players in the global chorea market are Teva Pharmaceutical Industries Ltd., Valeant, Medtronic, Alnylam Pharmaceuticals, Inc., Cyberonics, Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Boston Scientific Corporation, GlaxoSmithKline plc, Lundbeck, Prana Biotechnology Limited, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, SOM Biotech, Raptor Pharmaceutical, Omeros, Ipsen, Pfizer, Palobiofarma, Aleva Neurotherapeutics SA, and others.


Research Methodology
Chorea Market


Regional Analysis


The Americas dominate the chorea market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.


Europe holds the second position in the chorea market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.


Asia Pacific is the fastest growing chorea market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.


The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.



Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Chorea Market, by Type

6.1 Introduction

6.2 Huntington’s Disease

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Rheumatic (Sydenham’s chorea)

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Drug-Induced Chorea

6.4.1 Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Chorea Market, by Treatment

7.1 Introduction

7.2 Medical Care

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Surgical Care

7.3.1 Market Estimates & Forecast, 2020-2027

Chapter 8. Global Chorea Market, by Distribution Channel

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Clinics

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Diagnostic Centers

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Drug Stores

8.5.1 Market Estimates & Forecast, 2020-2027

8.6 Pharmacies

8.6.1 Market Estimates & Forecast, 2020-2027

8.7 Others

8.7.1 Market Estimates & Forecast, 2020-2027

Chapter 9. Global Chorea Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Teva Pharmaceutical Industries Ltd.

11.1.1 Company Overview

11.1.2 Type of Causative Agents Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Valeant

11.2.1 Company Overview

11.2.2 Type of Causative Agents Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Medtronic

11.3.1 Company Overview

11.3.2 Type of Causative Agents Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Alnylam Pharmaceuticals, Inc.

11.4.1 Company Overview

11.4.2 Type of Causative Agents/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Cyberonics, Inc.

11.5.1 Company Overview

11.5.2 Type of Causative Agents Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 AmpliPhi Biosciences Corp

11.6.1 Company Overview

11.6.2 Type of Causative Agents Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 CEREGENE INC.

11.7.1 Overview

11.7.2 Type of Causative Agents Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Chorea Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Chorea Industry Synopsis, 2020-2027

Table 2 Chorea Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Chorea Market by Region, 2020-2027, (USD Million)

Table 4 Chorea Market by Type, 2020-2027, (USD Million)

Table 5 Chorea Market by Treatment, 2020-2027, (USD Million)

Table 6 Chorea Market by Distribution Channels, 2020-2027, (USD Million)

Table 7 North America Chorea Market by Type, 2020-2027, (USD Million)

Table 8 North America Chorea Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Chorea Market by Distribution Channels, 2020-2027, (USD Million)

Table 10 US Chorea Market by Type, 2020-2027, (USD Million)

Table 11 US Chorea Market by Treatment, 2020-2027, (USD Million)

Table 12 US Chorea Market by Distribution Channels, 2020-2027, (USD Million)

Table 13 Canada Chorea market by Type, 2020-2027, (USD Million)

Table 14 Canada Chorea Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Chorea market by Distribution Channels, 2020-2027, (USD Million)

Table 16 South America Chorea Market by Type, 2020-2027, (USD Million)

Table 17 South America Chorea Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Chorea Market by Distribution Channels, 2020-2027, (USD Million)

Table 19 Europe Chorea Market by Type, 2020-2027, (USD Million)

Table 20 Europe Chorea Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Chorea Market by Distribution Channels, 2020-2027, (USD Million)

Table 22 Western Europe Chorea Market by Type, 2020-2027, (USD Million)

Table 23 Western Europe Chorea Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Chorea Market by Distribution Channels, 2020-2027, (USD Million)

Table 25 Eastern Europe Chorea market by Type, 2020-2027, (USD Million)

Table 26 Eastern Europe Chorea Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Chorea Market by Distribution Channels, 2020-2027, (USD Million)

Table 28 Asia Pacific Chorea Market by Type, 2020-2027, (USD Million)

Table 29 Asia Pacific Chorea Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Chorea market by Distribution Channels, 2020-2027, (USD Million)

Table 31 Middle East & Africa Chorea Market by Type, 2020-2027, (USD Million)

Table 32 Middle East & Africa Chorea Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Chorea market by Distribution Channels, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Chorea Market

Figure 3 Segmentation Market Dynamics for Chorea Market

Figure 4 Global Chorea market Share, by Type 2027

Figure 5 Global Chorea market Share, by Treatment 2027

Figure 6 Global Chorea market Share, by Distribution Channels, 2027

Figure 7 Global Chorea market Share, by Region, 2027

Figure 8 North America Chorea market Share, by Country, 2027

Figure 9 Europe Chorea market Share, by Country, 2027

Figure 10 Asia Pacific Chorea market Share, by Country, 2027

Figure 11 Middle East & Africa Chorea market Share, by Country, 2027

Figure 12 Global Chorea market: Company Share Analysis, 2027 (%)

Figure 13 Teva Pharmaceutical Industries Ltd.: Key Financials

Figure 14 Teva Pharmaceutical Industries Ltd. Segmental Revenue

Figure 15 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

Figure 16 Valeant: Key Financials

Figure 17 Valeant: Segmental Revenue

Figure 18 Valeant: Geographical Revenue

Figure 19 Medtronic: Key Financials

Figure 20 Medtronic: Segmental Revenue

Figure 21 Medtronic: Geographical Revenue

Figure 22 Alnylam Pharmaceuticals, Inc.: Key Financials

Figure 23 Alnylam Pharmaceuticals, Inc.: Segmental Revenue

Figure 24 Alnylam Pharmaceuticals, Inc.: Geographical Revenue

Figure 25 Cyberonics, Inc.: Key Financials

Figure 26 Cyberonics, Inc.: Segmental Revenue

Figure 27 Cyberonics, Inc. Geographical Revenue

Figure 28 AmpliPhi Biosciences Corp: Key Financials

Figure 29 AmpliPhi Biosciences Corp: Segmental Revenue

Figure 30 AmpliPhi Biosciences Corp: Geographical Revenue

Figure 31 CEREGENE INC.: Key Financials

Figure 32 CEREGENE INC.: Segmental Revenue

Figure 33 CEREGENE INC.: Geographical Revenue



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.